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Abstract
 
The foreign body reaction is one of the oldest host defense mechanisms against tissue damage
which involves inflammation, scarring, and encapsulation. The chemical carcinogen methyl-
cholanthrene (MCA) induces fibrosarcoma and tissue damage in parallel at the injection site.
Tumor development induced by MCA but not due to p53-deficiency is increased in inter-
feron-
 

 
 receptor (IFN-
 

 
R)–deficient mice. In the absence of IFN-
 

 
R, MCA diffusion and
DNA damage of surrounding cells is increased. Locally produced IFN-
 

 
 induces the formation
of a fibrotic capsule. Encapsulated MCA can persist virtually life-long in mice without inducing
tumors. Together, the foreign body reaction against MCA prevents malignant transformation,
probably by reducing DNA damage. This mechanism is more efficient in the presence of
IFN-
 

 
R. Our results indicates that inflammation and scarring, both suspected to contribute to
malignancy, prevent cancer in certain situations.
Key words: inflammation • tissue damage • tissue repair • encapsulation • immune surveillance
 
Introduction
 
Chemical carcinogens such as polycyclic aromatic hydro-
carbons (PAH)
 
* 
 
are contained in environmental pollutants
and appear to contribute to cancer in man (1). One type of
PAH is 3-methylcholanthrene (MCA) which has been
widely used in mice to analyze chemical carcinogenesis (2).
MCA usually induces tumors at the site of injection, for
unknown reasons often fibrosarcomas. Malignant transfor-
mation by MCA results from the stepwise accumulation of
mutations and selection of cells with the right mutations,
e.g., in protooncogenes like ras or tumor suppressor genes
like p53 (3, 4). MCA induces mutations in a random fash-
ion and many mutations might interfere with cell integrity.
Thus, MCA should induce tissue damage and malignant
transformation in parallel (5).
The repair process that follows injury in a variety of tissues
resembles the process of wound healing of the skin (6).
Wound repair in adult skin involves a series of overlapping
and highly orchestrated events involving inflammation,
reepithelialization, granulation tissue formation, and, finally,
scar formation (7). The inflammatory response to tissue
damage is characterized by the rapid influx of neutrophils
followed by the accumulation of macrophages. In the later
phases, fibroblasts become the dominant cell type. They
produce and deposit extracellular matrix, finally leading to
fibrosis or scar formation (6, 7).
Inflammation has been suspected to contribute to cancer
for a long time (for a review, see reference 8). Based on ob-
servations that carcinomas appear around the wound of skin
pretreated with carcinogen (9–11), the initiation/promotion
model of carcinogenesis has received much attention. Sub-
threshold amounts of PAH induce irreversible cellular
changes, probably by inducing first mutation(s). If the same
site is treated even after a long time with reagents like TPA
(12-
 
O
 
-tetradecanoylphorbol-13-acetate), which are not car-
cinogenic but induce inflammation, tumors can develop
(12). Tumor-promoting effects of inflammation have usually
been associated with late stages such as promotion or pro-
gression during chemical carcinogenesis (13). More recently,
this has been shown during tumor development in onco-
gene-transgenic mice or tumor suppressor gene–deficient
mice with defined inflammatory defects (14–16).
The foreign body reaction is characterized by encapsula-
tion of foreign material. Phylogenetically, it is one of the
oldest defense mechanism, predating adaptive immunity.
Encapsulation is a major defense mechanism in insects and
molluscs, e.g., if phagocytosis against larger parasites fails
(17–19). Even the phylogenetically old porifera can form a
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barrier by deposition of a fibrous wall at the interphase to
an allograft (20). Therefore, the foreign body reaction ap-
pears to be the most common mechanism in multicellular
organisms to keep tissue integrity. In man, it is commonly
associated with a pathological situation, typically described
as fibrous tissue capsule or scar surrounding foreign mate-
rial like talc crystals as remnants of a surgeon’s glove, artifi-
cal implants (21), or most dramatically upon exposure to
asbestos (22).
IFN-
 

 
 is produced by several cell types upon activation
(e.g., T, B, NK cells, macrophages, and mast cells; refer-
ences 23–27), but also appears to be constitutively present
at basal levels in nontreated mice (28). The pleiotropic ac-
tivities of IFN-
 

 
 are compatible with the ubiquitous ex-
pression of the IFN-
 

 
 receptor (IFN-
 

 
R). The immuno-
regulatory role of IFN-
 

 
 for T cell subsets, antigen
processing, or MHC expression is well established (23).
However, T cells in IFN-
 

 
R
 

 
/
 

 
 mice develop and pro-
duce IFN-
 

 
 normally (29) and can induce rejection of
transplanted tumors in IFN-
 

 
R
 

 
/
 

 
 mice (30). Effects of
IFN-
 

 
 on function of mesenchymal cells are less clear. It
was shown that IFN-
 

 
 downregulated fibroblast prolifera-
tion and connective tissue production (6). In contrast, re-
cent in vivo experiments showed that IFN-
 

 
 directly
caused growth factor–induced vascular smooth muscle cell
mitogenesis and arteriosclerosis which is associated with ac-
cumulation of extracellular matrix (31). We show here that
chemical carcinogenesis by MCA is inhibited in an IFN-
 

 
R–dependent fashion. Since we had no indications for T
cell involvement and the mechanism appeared to be differ-
ent from T cell–mediated tumor transplantation immunity,
we analyzed the local reaction to MCA in the primary
host. During the tissue repair response to MCA-induced
damage MCA is encapsulated and persists long-term within
microscopic scars in tumor-free mice.
 
Materials and Methods
 
Mice.
 
IFN-
 

 
R
 

 
/
 

 
 mice, generated as inbred 129/Sv/Ev line,
and congenic IFN-
 

 
R
 

 
/
 

 
 control mice were provided by M.
Aguet (Swiss Institute for Experimental Cancer Research, Lau-
sanne, Switzerland; reference 29). IFN-
 

 
R
 

 
/
 

 
 mice were gener-
ated by breeding IFN-
 

 
R
 

 
/
 

 
 with IFN-
 

 
R
 

 
/
 

 
 mice. For most
experiments, IFN-
 

 
R
 

 
/
 

 
 and IFN-
 

 
R
 

 
/
 

 
 mice were paired to
obtain IFN-
 

 
R–deficient and IFN-
 

 
R–competent control litter-
mates. BALB/c, BALB/c nu/nu mice, and mice homozygous for
the p53 tumor-suppressor gene (p53
 

 
/
 

 
 mice; reference 32) with
a mixed genetic background of 129/Sv/Ev and C57BL/6 were
obtained from Bomholtgaard Breeding Facilities, Denmark. The
p53 and IFN-
 

 
R double knockout mice were generated by
breeding a single p53
 

 
/
 

 
 male with several IFN-
 

 
R
 

 
/
 

 
 female
mice. F1 mice were intercrossed to obtain p53
 

 
/
 

 
IFN-
 

 
R
 

 
/
 

 
,
p53
 

 
/
 

 
IFN-
 

 
R
 

 
/
 

 
, p53
 

 
/
 

 
IFN-
 

 
R
 

 
/
 

 
, and p53
 

 
/
 

 
IFN-
 

 
R
 

 
/
 

 
mice. Genomic typing of mice was performed by PCR as de-
scribed previously (29, 32). All mice except for nude mice were
bred in the animal facility of the Max-Delbrueck-Center of Mo-
lecular Medicine under germ-poor conditions. They were regu-
larly tested and found free for a panel of pathogens (available
upon request) throughout the study.
 
Tumor Induction.
 
MCA-induced tumorigenesis in IFN-
 

 
R–
competent and –deficient mice was analyzed beginning in 1994 in
three subsequent experiments. Mice were injected intramuscularly
in the left hind leg with different amounts of MCA (Sigma-
Aldrich) suspended in 0.1 ml of sesame oil. Tumor development
was observed 2–3 times weekly for 1.5–2 y. Mice with a tumor
 

 
10 mm in diameter were counted as tumor positive. Spontane-
ous tumor development in the absence of one or both p53 alleles
was monitored 1–3 times weekly. Mice were killed when they had
an overt mass of 
 

 
15 mm or appeared moribund. The diagnosis of
tumors was done by macroscopic analysis of different organs, mi-
croscopy of peripheral blood smears, and histological analysis.
 
Tumor Cell Lines.
 
MCA-induced primary tumors from IFN-
 

 
R
 

 
/
 

 
 and IFN-
 

 
R
 

 
/
 

 
 mice (H-2
 
b
 
) were surgically excised and
passaged as tumor fragment (4 
 

 
 4 
 
 
 
4 mm) in BALB/c nu/nu
mice (H-2
 
d
 
) to minimize the contamination of stromal cells
from primary tumor-bearing mice during flow cytometric anal-
ysis. The passaged tumors were minced, trypsin-treated for 5
min at 37
 

 
C, and maintained by culture in RPMI 1640 medium
supplemented with 10% FCS. J558-IFN-
 

 
 and J558-LT cells
have been described previously (33, 34). 5 
 

 
 10
 
5
 
 of the cytokine
gene transfected cells produce 10 ng/ml IFN-
 

 
 as measured by
ELISA or 330 U/ml LT in 24 h as measured by L929 cytolytic
assay, respectively.
 
Flow Cytometric Analysis.
 
Tumor cells prepared as above and
cultured in the third passage were stained with FITC-conjugated
mAbs against H-2D
 
b
 
 (HK95), H-2K
 
b
 
 (AF6–88.5), I-a
 
b
 
 (06044D),
or isotype-matched control mAb, rat IgG
 
2b
 
 (11034C) and rat
IgG
 
2a
 
 (11024C; BD PharMingen). To ascertain the success of
bone marrow reconstitution of IFN-
 

 
R
 

 
/
 

 
 and IFN-
 

 
R
 

 
/
 

 
mice, 3 mo after bone marrow transplantation, peripheral blood
cells were stained with mAbs specific for murine B220, CD4,
CD8, and GR-1 in combination with anti–IFN-
 

 
R mAb (GR-
20; BD PharMingen). As control isotype-matched rat Ig was used.
Three mice from each group were analyzed. All samples were an-
alyzed with an Epics-XL flow cytometer (Beckman Coulter).
 
Tumor Fragment Transplantation.
 
To avoid phenotypic changes
during in vitro culture, instead of cultured tumor cells, tumor
fragments were used to analyze tumor growth. MCA-induced tu-
mors from primary tumor-bearing mice were surgically isolated
and cut into pieces of 4 
 

 
 4 
 

 
 4 mm. The tumor fragments were
then subcutaneously transplanted onto IFN-
 

 
R
 

 
/
 

 
 mice in the
left side of abdomen. The growth of tumors was monitored every
2–3 d. Together, five IFN-
 

 
R
 

 
/
 

 
 and five IFN-
 

 
R
 

 
/
 

 
 tumors
were analyzed.
 
Bone Marrow Chimera.
 
Freshly prepared bone marrow cells of
6–8-wk-old IFN-
 

 
R/ or IFN-R/ mice were harvested
from femurs and tibiae and 107 cells were injected intravenously
into lethally irradiated (10 Gy) age- and sex-matched mice. The
following groups were included: IFN-R/ → IFN-R/;
IFN-R/ → IFN-R/; IFN-R/ → IFN-R/; and
IFN-R/ → IFN-R/. Successful reconstitution of the he-
matopoietic system was determined by flow cytometric analysis
of peripheral blood mononuclear cells for IFN-R expression.
Additionally, chimerism of mice was confirmed by PCR analysis
of the IFN-R gene using tail DNA that contained genomic
DNA from both nonhematopoietic and hematopoietic cells.
Histology. Mice were intramuscularly injected with MCA in
the left hind leg and after the indicated periods, tissue from the
injection site was isolated and cryostat sections were prepared.
MCA was detected by light microscopy on Hematoxylin-stained
sections and by fluorescent microscopy. We noticed that acetone
fixation could lead to loss of MCA from the tissue section. For
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immunohistological analysis, alkaline phosphatase staining was
done as described previously (35). The mAbs used were anti-
CD4 (RM4–4), anti-CD8 (53–6.7), anti–Mac-1 (M1/70), anti–
Gr-1 (RB6–8C5) (BD PharMingen), anti-fibroblast/extracellular
matrix (ER-TR7) (BMA, Augst, Swiss), anticollagen I-V (2150–
2206) (Biotrend), and isotype-matched control mAbs. Alkaline
phosphatase-conjugated goat anti–rat IgG and rabbit anti–goat
IgG were purchased from Jackson Immunoresearch Laboratories.
To analyze the effect of local IFN- production on extracellular
matrix deposition, 5  106 J558-IFN- and as control, J558-LT
cells were injected subcutaneously into nude mice and tumor tis-
sue was obtained after 3–4 wk. Collagen was visualized by Ver-
hoeff-van Gieson staining. To detect DNA damage on MCA-
containing sections, an in situ cell death detection kit was used
according to the manufacturer’s instructions (Boehringer Mann-
heim). The breaks of single- or double-stranded DNA are visual-
ized by terminal deoxynucleotidyl transferase-mediated dUTP
nick end labeling (TUNEL).
Diffusion of MCA/Oil. Abdominal skin of mice was shaved or
depilated with Veet Sensitive Plus Enthaarungs-Creme (Reckitt
Benckiser) and 0.8 mg of MCA in 0.2 ml sesame oil was subcuta-
neously injected into the depilated area, causing a bubble-like
swelling. Mice were weekly observed for persistence of the bubble
(2 mm in diameter). In parallel, histological analysis confirmed
that the swelling was always due to the local presence of MCA/oil.
Results
Low Incidence of MCA-induced Tumors in IFN-R–compe-
tent Compared with IFN-R–deficient Mice without Evidence of
Immune Selection. IFN-R/, IFN-R/, and IFN-
R/ mice were injected intramuscularly with 0.8 mg
MCA and tumor development was observed for 80 wk. In
repeated experiments, IFN-R/ mice developed tumors
earlier and with higher frequency compared with IFN-
R/ or IFN-R/ mice. For example, all male IFN-
R/ (35/35) but only 44% (16/36) IFN-R/ mice
had developed tumors at week 38 (Fig. 1 a). At week 80,
31% of the male IFN-R/ mice remained tumor free.
Similar results were observed with female mice (Fig. 1 a).
IFN-R/ and IFN-R/ mice developed tumors with
similar frequency and kinetics (Fig. 1 b). If mice were
treated with lower amounts of MCA, namely, 0.3 mg (Fig.
1 c) or 0.1 mg (Fig. 1 d), the difference in tumor incidence
between IFN-R/ and IFN-R/ group was again sig-
nificant. To ask whether the decreased tumor development
in IFN-R–competent mice was associated with signs of
immune selection, tumors of IFN-R/ and IFN-R/
mice were analyzed for some indicative cell surface mark-
Figure 1. Inhibition of MCA-induced tumori-
genesis in 129Sv/Ev IFN-R/ and IFN-R/
compared with IFN-R/ mice without evidence
of immune selection. (a–d) Tumor incidence. 6–10-
wk-old IFN-R/ (white symbols) and IFN-R/
(black symbols) male ( and ) or female mice (
and ) were intramuscularly injected with (a and
b) 0.8 mg, (c) 0.3 mg, and (d) 0.1 mg MCA, and
tumor development was monitored. Mice with a
tumor of 10 mm were recorded as tumor posi-
tive. In b, tumor incidence in IFN-R/ female
mice () was also shown. The number of mice/
group is indicated. In a, one out of three experi-
ments with similar results is shown. (e) Expression
of MHC-molecules on MCA-induced IFN-R/
(white) and IFN-R/ (black) tumor cells. Cells
were stained with FITC-conjugated mAbs against
H-2Kb, H-2Db, and I-ab. Shown are folds of mean
channel fluorescence above background. Each sym-
bol represents the staining of one primary cell culture.
(f) Similar growth of IFN-R/ and IFN-R/
tumors in wild-type mice. Fragments of MCA-
induced tumors (4  4  4 mm) were transplanted
subcutaneously onto IFN-R/ mice. Tumor size
was monitored every 2–3 d. Shown are days re-
quired for a tumor to grow to the size of 10 mm.
Each symbol represents the growth of one pri-
mary tumor grafted onto 3–4 recipient mice. Five
IFN-R/ (white) and five IFN-R/ tumors
(black) were analyzed.
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ers. Overall, expression of MHC class I (Db and Kb), MHC
class II (Fig. 1 e), vascular cell adhesion molecule 1, intra-
cellular adhesion molecule 1, B7.1, and B7.2 molecules
(data not shown) was similar in tumors of both groups.
IFN-R/ and IFN-R/ tumor fragments were trans-
planted onto IFN-R/ recipients. As can be seen in Fig.
1 f, tumors of both groups grew with similar kinetics.
Therefore, more efficient control of MCA-induced car-
cinogenesis in the presence of IFN-R occurred without
obvious indications of immune selection.
IFN-R Expression by Either Bone Marrow– or NonBone
Marrow–derived Cells Is Sufficient to Inhibit MCA-induced Tu-
mor Development. Previously, we showed that T cell–medi-
ated tumor transplantation immunity required IFN-R ex-
pression by nonhematopoietic but not hematopoietic or
tumor cells (30). To ask whether control of chemical car-
cinogenesis involved similar mechanisms, bone marrow
chimeras were generated and 3 mo after reconstitution
challenged with MCA. Comparison of tumor development
between IFN-R/ → IFN-R/ and IFN-R/ →
IFN-R/ bone marrow chimeric mice confirmed that
IFN- responsiveness decreased tumor incidence (Fig. 2).
Surprisingly, both IFN-R/ → IFN-R/ and IFN-
R/ → IFN-R/ groups of mice showed decreased
tumor development, similar to the IFN-R/ → IFN-
R/ mice. Thus, IFN-R expression by either bone
marrow– or nonbone marrow–derived cells was able to in-
hibit MCA-induced carcinogenesis. This suggested that
control of chemical carcinogenesis is mechanistically differ-
ent from that of transplanted tumors.
Tumor Development Due to p53 Deficiency Is Not Changed in
IFN-R/ Compared with IFN-R/ Mice. To analyze
whether the IFN-R–mediated control mechanism is also
operative against spontaneous tumor development, we
generated mice defective in both IFN-R and p53 genes.
p53-deficient mice are healthy at birth and invariably de-
Figure 2. IFN- responsiveness of either bone marrow–derived or
nonbone marrow–derived cells is sufficient for inhibition of MCA-
induced tumorigenesis. IFN-R/ (white) and IFN-R/ mice (black)
were lethally irradiated and reconstituted with bone marrow cells from
mice with the same ( and ) or different genotype ( and ). 3 mo af-
ter reconstitution mice were intramuscularly injected with 0.8 mg MCA
in the left hind leg and tumor development was monitored. Each group
contained 7–11 mice. Shown is the experiment with male mice. Similar
results were obtained when female mice were analyzed.
Figure 3. Tumor development due to
p53-deficiency is not changed in IFN-R/
compared with IFN-R/ mice. IFN-
R/p53/ (), IFN-R/p53/
(	), IFN-R/p53/ (), and IFN-
R/p53/ mice () were monitored for
tumor development. Results from female
(top) and male mice (bottom) are plotted
separately. Mice, which were moribund or
had a solid tumor of 15 mm, were recorded
as tumor positive. No significant difference
in tumor types between IFN-R/ and
IFN-R/ mice was detected. Number of
mice per group is given in parenthesis.
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velop tumors (32). Importantly, malignant transformation
by p53 deficiency occurs in a silent way as opposed to
MCA-induced carcinogenesis, which is accompanied by
tissue damage (see below). Fig. 3 shows tumor develop-
ment in IFN-R/ and IFN-R/ mice with one or
both defective p53 alleles. In either case, no difference in
tumor development was observed between IFN-R/
and IFN-R/ mice. For example, 50% male IFN-
R//p53/ mice developed a tumor at week 59 and
100% at week 98. IFN-R//p53/ mice developed a
tumor at week 60 to 50% and week 97 to 100%, respec-
tively. IFN-R//p53/ and IFN-R//p53/ mice
also developed tumors with similar kinetics. There were no
significant differences in the tumor spectrum between
IFN-R/ and IFN-R/ mice (data not shown). Thus,
we could not detect an IFN-R–mediated mechanism that
inhibited spontaneous tumor development.
Tissue Repair Response and Fibrosis at the Site of MCA.
The results so far led us to analyze the local reaction to
MCA. Sections of MCA-injected tissues of IFN-R/
and IFN-R/ mice were analyzed for the presence of
MCA at different time points after injection (each 3–5
mice at weeks 3, 4, 6, 10, and 20). Regardless of the time
after injection and the mouse genotype, MCA was always
detected by light microscopy as crystalline structures within
the muscle tissue (Fig. 4 a and c). To confirm that these
structures were indeed MCA, we made use of the fact that
MCA is a polycyclic aromate and can become visible on
tissue sections through auto-fluorescence (Fig. 4 b). Addi-
tionally, MCA was associated with local tissue damage.
Consecutive tissue sections containing MCA from the
above-mentioned mice were analyzed for the presence of
cells positive for Mac1, Gr1, CD4, CD8, and /	 T cell
receptor. /	 (data not shown) and CD8 T cells were
Figure 4. Tissue repair response and fibrosis at the site of MCA. IFN-R/ and IFN-R/ mice were injected intramuscularly with 0.8 mg MCA
and tissue sections were prepared 3, 4, 6, 10, and 20 wk after injection (3–5 mice per time point and mouse strain). (a) MCA detected under light and (b)
fluorescence microscope. (c) shows numbers of mice in which MCA was detected per numbers of total mice examined at different time points. (d–f) In-
flammation at the site of MCA. Consecutive sections of the MCA-containing sections in c were confirmed to also contain MCA and then stained with
various mAbs. Since inflammation between IFN-R/ and IFN-R/ was similar, one example for (d) anti-Mac1 and (e) anti-Gr1 staining of tissue
sections prepared 10 wk after MCA injection is shown. (f) Summary of the immunohistological staining for Mac1, Gr1, CD4, and CD8 positive cells of
the IFN-R/ (white) and IFN-R/ mice (black) shown in c. Shown are mean numbers of the indicated inflammatory cells surrounding MCA in
one optical field with 100 magnification. (g–i) Fibroblast accumulation and fibrosis at the MCA-injection site. (g) mAb ER-TR7 staining of a muscle
tissue section of a control mouse not injected with MCA and (h) a tissue section with MCA prepared 10 wk after MCA-injection. (i) Hematoxylin stain-
ing of a tissue section prepared 20 wk after MCA injection showing fibroblasts closely surrounding a piece of MCA. Fibroblast accumulation at the site of
MCA was similarly observed in IFN-R/ and IFN-R/ mice and at the different time points. (j) Detection of microscopic fibrosarcoma near MCA.
20 wk after MCA injection an early fibrosarcoma with reduced ER-TR7 expression was detected microscopically in two of the IFN-R/ mice. Orig-
inal magnifications: 400 (i) and 100 (others).
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only occasionally detected at the site of MCA in both
groups of mice. CD4 T cells appeared to be more abun-
dant and occurred in similar amounts in IFN-R/ and
IFN-R/ mice. Large numbers of Mac1 (Fig. 4 d) and
Gr1 cells (Fig. 4 e) were detected in close vicinity to
MCA. This was similar at the different time points and be-
tween IFN-R/ and IFN-R/ mice, even though we
cannot exclude subtle differences in the strength of the in-
flammatory reaction. The cumulative data of the immuno-
histochemical analysis are summarized in Fig. 4 f.
Considering that MCA usually induces fibrosarcomas at
the injection site and that fibroblasts accumulate at sites of
tissue damage, MCA-containing tissue sections were stained
with an antibody specific for fibroblasts and extracellular
matrix (mAb ER-TR7). Staining of normal muscle tissue
sections showed an ordered net-like structure of fibroblasts
closely surrounding muscle cells (Fig. 4 g). At the site of
MCA, a dramatic accumulation of fibroblasts was detected
(Fig. 4 h and i). This was observed similarly in IFN-R/
and IFN-R/ mice and also at the different time points
after MCA injection. Thus, fibroblasts might be directly ex-
posed to the mutagenic activity of MCA. In fact, in two out
of five IFN-R/ mice analyzed at week 20 after MCA
treatment tumors were detected which had strongly re-
duced expression of the fibroblast marker (Fig. 4 j). It is
known that tumors derived from fibroblasts often downreg-
ulate cell type–specific markers (36). Together, the local re-
action at the site of MCA resembles a tissue repair response,
similarly in IFN-R/ and IFN-R/ mice.
Local IFN- Production Induces a Collagenous Capsule.
Because control of MCA-induced carcinogenesis required
IFN- responsiveness, IFN- should be locally available.
To analyze the effects of local IFN- production on the
surrounding tissue and extracellular matrix formation, we
used the tumor line J558L transfected to secrete IFN-
(J558-IFN-). We knew that tumor growth of these cells is
strongly delayed in nude mice due to IFN- secretion (33).
Sections of J558-IFN- tumors grown in nude mice
showed that a collagenous capsule clearly separated the
whole tumor from neighboring tissue (Fig. 5 a and c). To
demonstrate that the formation of extracellular matrix was
specific for IFN-, we used as a control the same tumor
transfected to secrete lymphotoxin (J558-LT; reference 34).
Both tumor cell lines grew with similar kinetics in nude
mice (data not shown). No collagenous capsule but only
scattered collagen fibers could be detected for the J558-LT
tumor (Fig. 5 b and d). Therefore, the local IFN- produc-
tion led to encapsulation of transplanted tumor cells.
Inhibition of MCA Diffusion in IFN-R/ Compared with
IFN-R/ Mice. Next, a possible relevance of the IFN-
–induced collagenous capsule for decreased MCA-induced
carcinogenesis in IFN-R/ compared with IFN-R/
mice was analyzed. MCA is usually injected as a viscous
sesame oil emulsion that diffuses slowly from the injection
site. To monitor this diffusion process, MCA/oil emulsion
was subcutaneously injected into IFN-R/ and IFN-
R/ mice and the kinetics of diffusion was determined.
MCA injected subcutaneously or intramuscularly induces
tumors with a similar kinetics. In the majority of IFN-
R/ mice, swelling caused by the MCA/oil emulsion
was visible during a 7-wk period of observation (Fig. 6 a).
In contrast, beginning at week 2, a macroscopically visible
Figure 5. Local production of
IFN- induces a collagenous
capsule. Nude mice were subcu-
taneously injected with 5  106
(a and c) J558-IFN- or (b and
d) J558-LT tumor cells. 3–4 wk
later, when tumors had grown to
a size of 10 mm in diameter,
paraffin sections were prepared
and stained for collagen by the
Verhoeff-van Gieson method.
The arrow indicates a wall-like
collagenous capsule separating
normal and tumor tissue. Origi-
nal magnification: (a and b)
100; (c and d) 400. Results
are representative for tumor sec-
tions of 3–5 mice per group.
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swelling disappeared in most of the IFN-R/ mice indi-
cating that IFN- responsiveness causes inhibition of the
MCA/oil emulsion to diffuse from the injection site. Im-
munohistochemical analysis showed a similar accumulation
of Mac1 and Gr1 cells at the injection site as seen for
MCA in the muscle (data not shown).
Decreased Tissue Damage at the Site of MCA in IFN-R/
Compared with IFN-R/ Mice. MCA induces random
mutations. One can expect that many of the mutations do
not create a growth advantage and even decrease cell sur-
vival. Probably, only in a minority of cases mutations
cause a growth advantage and finally malignant transfor-
mation. Therefore, cell death and malignant transforma-
tion should happen in parallel. As a measurement for ex-
posure of nearby cells to the mutagenic activity of MCA
we used the TUNEL-technique which detects DNA-
breaks. Tissue sections of IFN-R/ and IFN-R/
mice were analyzed at weeks 3, 4, 6, 10, and 20 after
MCA injection (the mice which are shown in Fig. 4 c).
An example of TUNEL-staining at the site of MCA 10
wk after injection is shown for IFN-R/ and IFN-
R/ mice (Fig. 6 b and c). Significantly more DNA
breaks were detected in IFN-R/ compared with IFN-
R/ mice. TUNEL staining always occurred in close
vicinity to MCA. The cumulative data of all stainings are
expressed as relative index for DNA damage (Fig. 6 d). At
all time points, less DNA breaks were detected in IFN-
R/ compared with IFN-R/ mice. In IFN-R/
mice, DNA breaks were decreased but not absent which is
compatible with the fact that only a part of the mice re-
mained long-term tumor free.
Encapsulated MCA Persists in Long-Term Tumor-free Mice.
Taking the above experiments together, the question arose
whether encapsulated MCA could be identified in long-
term tumor free mice. To exclude mouse strain-specific
effects (129/Sv/Ev are more resistant to MCA-induced
carcinogenesis compared with BALB/c mice), decreasing
amounts of MCA were injected into BALB/c mice antici-
Figure 6. IFN-R–dependent inhibition of MCA-diffusion and protection from tissue damage. (a) Inhibition of MCA diffusion. IFN-R/ () and
IFN-R/ mice () were subcutaneously injected with 0.8 mg MCA in 0.2 ml sesame oil emulsion and the swelling of the injection site was moni-
tored every week. The swelling with a size of 2 mm in diameter was recorded as positive. Shown is the percentage of mice with MCA/oil swelling vis-
ible at the injection site. Numbers of mice in each group are indicated. (b–d) Reduced tissue damage in IFN-R/ compared with IFN-R/ mice.
Groups of mice (3–5 per time point and mouse strain; see Fig. 4 c) were injected i.m. with 0.8 mg MCA in sesame oil and tissue sections were prepared
at indicated time points after injection. Tissue sections were confirmed to contain MCA (visible as black crystals) and then stained for DNA breaks by the
TUNEL technique. Staining results were arbitrarily evaluated as an index for DNA-damage from 1 to 4. As an example stainings of a section from an (b)
IFN-R/ and (c) IFN-R/ mouse 10 wk after MCA injection with an index of 1 and 4, respectively, are shown. (d) The mean indexes for DNA-
damage of IFN-R/ (white bar) or IFN-R/ mice (black bar) at different time points after MCA injection.
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pating that at a given dose some mice would not develop a
tumor (Fig. 7 a). For example, if 0.1 mg MCA were in-
jected, 82% of the mice had developed a tumor by week 24
and the remaining mice stayed tumor-free for 1 y. This
indicated that the process of malignant transformation was
terminated. At that time, serial tissue sections of injected
muscles were analyzed for the presence of MCA. In eight
out of nine mice, injected 65–75 wk ago, MCA was de-
tected (Fig. 7 b). MCA was usually embedded within a
cluster of cells with an altered morphology (compare Fig. 7
b and Fig. 4 i). A collagenous capsule around MCA was
observed by staining with the antifibroblast/extracellular
matrix mAb ER-TR7 (Fig. 7 c) and a pan-anti-collagen
mAb (Fig. 7 d). Only few inflammatory cells (Mac1 and
Gr1) could be detected at these late time points (data not
shown). Thus, MCA can persist within microscopic scars in
tumor-free mice for a long time.
Discussion
Our data suggest that in the course of a tissue repair re-
sponse MCA is encapsulated. This limits tissue injury as
well as malignant transformation. Encapsulated MCA per-
sists virtually life-long in tumor-free mice. The IFN-R/
mice control chemically induced but not spontaneous tu-
mor development. This appears to be related to IFN-–
regulated extracellular matrix deposition. The results show
a protective role of an innate inflammatory response in the
early phase of chemical carcinogenesis. The foreign body
reaction as a protective mechanism to control chemical car-
cinogenesis sheds new light on scar cancer and is distinct
from Burnet’s concept of immunosurveillance.
Inflammation and Cancer. There is strong evidence that
inflammation can cause or contribute to cancer (8, 14). In
some cancer-prone mice (e.g., transgenic for ras) induction
of inflammation-induced tumors (37). In others (e.g.,
transgenic for polyoma middle T antigen, HPV16, or de-
fective for the tumor suppressor gene APC), inhibition of
inflammation or defects of inflammatory cells reduced tu-
mor formation (14–16). A tumor-promoting role of in-
flammation during chemical skin carcinogenesis has re-
cently been suggested, since TNF/ mice were resistant to
carcinogenesis (13). These models suggest that inflamma-
tion supported tumor growth at a comparably late phase,
e.g., promotion or progression. Inflammation at the site of
MCA occurred during an early stage and was associated
with inhibition of tumor development. The type of inflam-
matory cells (macrophages, granulocytes, and fibroblasts)
and tissue damage at the site of MCA suggest a tissue repair
response which correlated with decreased MCA diffusion,
Figure 7. Encapsulated MCA persists in long-term tumor free mice. (a) BALB/c mice were injected intramuscularly with 300 
g (), 100 
g (), or
30 
g () of MCA in sesame oil as indicated. Tumor development was monitored every 2–3 d and mice with a tumor of 10 mm were recorded as tu-
mor positive. Each group contained 12–16 mice. *Long-term tumor-free mice were killed at the indicated time points and the analysis of tissue sections
revealed microscopic fibrosis and encapsulated MCA. (b–d) Example stainings of the encapsulated MCA 65–75 wk after injection: (b) with Hematoxylin
only, (c) mAb ER-TR7 for fibroblasts and extracellular matrix and, (d) a pan-collagen specific mAb. Inlet figures in b and c show a piece of encapsulated
MCA at higher magnification. Original magnifications: (b and c) 100; (d): 200.
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tissue damage and malignant transformation in an IFN-
R–dependent fashion. Inflammation at the site of MCA
was observed in both, IFN-R/ and IFN-R/ mice,
indicating qualitative rather than quantitative differences. T
cells were, at all time points, only a minority at the site of
MCA, compatible with a tissue repair response. Most
prominent were fibroblasts which closely surrounded
MCA and might be the cell type mostly exposed to mu-
tagenic hits. Therefore, it is not surprising that MCA typi-
cally induces fibrosarcomas. The relationship between in-
flammation and cancer may be more complicated than
currently believed, if the stimulus for inflammation, e.g.,
carcinogen-induced tissue damage versus hyperplastic tis-
sue, or the time point of inflammation are considered.
The Foreign Body Reaction. The foreign body reaction is
characterized by encapsulation of foreign material. It is
phylogenetically one of the oldest defense mechanisms pre-
dating adaptive immunity, a major protective mechanism
in invertebrates and usually observed as a pathological reac-
tion in humans. We found that in the course of a tissue re-
pair response MCA was encapsulated and remained quasi
life-long in tumor-free mice within microscopic scars. The
high susceptibility to chemical carcinogenesis in IFN-R/
mice was associated with increased diffusion of MCA
from the injection site and more pronounced DNA dam-
age as shown by the TUNEL staining. Since locally pro-
duced IFN-–induced collagenous capsule formation, the
results suggest that fibroblasts in the vicinity of MCA de-
posited–extracellular matrix that protected the local tissue
and themselves from mutations. This process was more ef-
ficient in IFN-R-competent mice. It is interesting to note
that MCA-induced fibrosarcomas down-regulate expres-
sion of extracellular matrix proteins (36, 38, 39). PAHs are
ubiquitous environmental pollutants, they are very stable
(40) and can accumulate in the lung (41–44). Since human
exposure to benzo(a)pyrene has been estimated at 17 ng av-
erage daily intake from the air (45), one function of the
foreign body reaction could be to protect from (frequent)
tissue damage and concomitantly from (rare) malignant
transformation by carcinogens.
Our results shed new light on the mechanism how tu-
mor promotors which are not carcinogenic could enhance
tumor development at PAH-treated sites after a long time
period. Tumor-promotors like TPA induce inflammation.
It is thought that initiated cells acquire additional muta-
tions, because they are forced into DNA replication or
through oxidative damage increased in inflamed tissues (8).
A not exclusive alternative is that during tissue remodel-
ling, an obligatory step during inflammation, extracellular
matrix is degraded and MCA is set free to induce additional
mutations. TPA, for example, causes a stable reduction of
dermal collagen content in mouse skin which appears to be
a prerequisite of tumor development (46).
G. Friedrich (47) and R. Rössle (48) found in a series of
patients (frequently smokers) that lung carcinomas grew at
sites of scars. They suggested that scars predisposed to can-
cer be termed Narbenkrebs (scar cancer). Scars within the
carcinomas had an immature phenotype (increased col-
lagen type 3 content) indicative for an early stage of fi-
brotic process, whereas scars at some distance from the
neoplasm revealed a mature, late stage of the fibrotic pro-
cess (decreased type 3 and increased type 1 and 4 collagen)
(49). Our results indicate that scars can be protective as the
end product of MCA-encapsulation. Whether scar cancer
results from inefficient encapsulation of carcinogen is not
yet known, however, benzo(a)pyrene was detected in sub-
stantial amounts in lung tissues of smokers (41, 44) and
former smokers retain a substantial risk of developing lung
cancer (50).
The Role of IFN-/IFN-R during Protection from Chemical
Carcinogenesis. Two results at least partially explain the
role of IFN-/IFN-R during inhibition of chemical car-
cinogenesis. First, MCA diffused more rapidly from the in-
jection site in IFN-R/ compared with IFN-R/
mice which is reminiscent to the phenotype of IFN-R
deficiency in humans. These patients have a selective defect
in granuloma formation. Disseminated diseases occurred
when they were infected with mycobacteria and perhaps
also other intracellular bacteria (51, 52). Granuloma forma-
tion is an early event during mycobacteria infection which
involves encapsulation promoted by fibrosis (53). Since the
patients apparently respond normally to other infections
which do not involve granuloma formation, e.g., against
viruses, it is possible that the defective granuloma forma-
tion due to IFN-R deficiency led to ineffective encapsu-
lation and bacterial dissemination. Second, the local IFN-
production led to extracellular matrix accumulation and
encapsulation of IFN-–producing cells. Whether this is a
direct or indirect effect of IFN- is not known. For inhibi-
tion of chemical carcinogenesis IFN-R expression by ei-
ther hematopoietic or nonhematopoietic cells was suffi-
cient. This indicates that cells from both fractions can be
induced by IFN- to produce factors involved in extracel-
lular matrix accumulation. For example, IFN- upregulates
PDGF and PDGF-receptor expression by vascular smooth
muscle cells during artheriosclerosis (31). Similarly, IFN-
induces PDGF expression by monocytes/macrophages.
A Mechanism Different from Immunosurveillance. Burnet
proposed that cells derived from a ‘thymus-dependent sys-
tem’ recognize and eliminate frequently arising ‘potentially
dangerous mutant cells’, termed immunosurveillance (54).
In modern terms it postulates that T cells spontaneously
recognize an immunogenic, e.g., mutant, peptide in a
MHC-restricted fashion, become activated and destroy the
tumor cells. Immunosurveillance against virus-associated
tumors has been demonstrated (55), but it does not seem to
play a role in preventing the development of most forms of
cancers induced by chemical or physical carcinogens (56).
Our results support the existence of a spontaneous mecha-
nism controlling MCA-induced tumor development that,
however, differs from immunosurveillance. It is operative
during MCA-induced carcinogenesis but not during spon-
taneous tumor development (by p53 deficiency). Even
though we cannot exclude the participation of T cells, we
have no indications for their involvement. We could detect
only few T cells at the site of MCA during the first 20 wk
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and we did not see signs of immunselection in IFN-R–
competent mice. Importantly, nude mice lacking thymus-
dependent T cells and SCID mice lacking B cells and all T
cells (/, /	, and NK T cells) do not develop MCA-
induced tumors faster or more frequently (57, 58). A coin-
cidental finding in the latter study was that, despite similar
growth kinetics, tumors from SCID mice grew less fre-
quent upon transplantation into wild-type mice. This ar-
gues against the concept of immunselection but indicates
that the tumor is conditioned in the primary host for subse-
quent growth in recipient mice. Prehn and Bartlett had al-
ready shown that there existed no strict correlation
between latency period of MCA-induced tumors and im-
munogenicity tested by tumor transplantation experiments
(59). Our preliminary data of MCA-induced carcinogenesis
in CB17-SCID and recombination activation gene 1–defi-
cient mice showed a 3–4 wk delay in tumor development
compared with control CB17 and C57Bl/6 mice (data not
shown). Since we did not use control litter mates in these
experiments, a contribution of T cells has to be investigated.
Indeed, a little difference in tumorigenesis (3–4 wk) could
also be found when the same inbred mice from different
sources were compared (data not shown). It is known that
the genetic background can dramatically change suscepti-
bility to chemical carcinogenesis independent of immuno-
competence (2, 60).
Tumor transplantation immunity is usually mediated by
T cells. It is not clear whether transplantable tumor models
can explain the mechanism by which MCA-induced car-
cinogenesis is inhibited. Since bone marrow chimera ex-
periments argue against this possibility (Fig. 2 and reference
30), we analyzed the local events in the MCA-treated host.
This revealed a tissue repair response that can occur in the
absence of T cells. Therefore, our data suggest that MCA-
induced carcinogenesis is controlled by a mechanism differ-
ent from immunosurveillance and that the target for tumor
inhibition is primarily MCA and not tumor cells. Preven-
tion of tumor development by encapsulation of mutagens
should be more effective than killing transformed cells.
While this study was in progress, other studies showed
that tumor development induced by MCA was increased in
perforin-, IFN-, IFN-R-, TCR-J281 (NK T cell), and
recombination activation gene 2–deficient mice during an
observation period of up to 33 wk (61–65). Based on tu-
mor transplantation experiments, the authors suggested a
mechanism related to immunosurveillance. We do not
want to exclude this possibility, however, it needs to be
shown in the primary MCA-treated host that a tumor ap-
peared and was subsequently eliminated. Kaplan et al. (62)
found an increased incidence of tumors in p53/ mice if
IFN-R was also deficient. Since we did not find any
difference between p53//IFN-R/ compared with
p53//IFN-R/ mice, we also compared tumor inci-
dence between p53//IFN-R/ and p53//IFN-
R/ mice. These mice develop tumors after a long
latency period and should reveal a change in tumor inci-
dence or kinetics more easily, but again no difference was
observed. We could also not detect significant differences
in the tumor spectrum between these groups. Although the
reason for the discrepancy is not clear, the mixed genetic
background of p53-deficient mice (C57Bl/6  129Sv/Ev)
could be a problem. It has been shown that 129Sv and
C57Bl/6  129Sv p53/ mice differ in tumor kinetics
and spectrum (32). In conclusion, the relative contribution
of immunosurveillance versus the mechanism proposed
here requires further investigations, e.g., to answer the
question why recombination activation gene 2/ but not
SCID mice, two strain with similar phenotype, have in-
creased susceptibility to MCA-induced carcinogenesis (58,
64). Our results suggest that the primary mechanism which
controls chemical carcinogenesis is a tissue repair response
and foreign body reaction during which IFN-R plays a
not yet completely understood role.
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